Capecitabine as Maintenance Therapy vs Observation in Early-stage Triple-negative Breast Cancer
Status:
COMPLETED
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
Eligible patients was assigned in a 1:1 ratio to receive either low-dose capecitabine maintenance (intervention group) which is newly diagnostic to be planned to receive capecitabine after finishing the standard adjuvant treatment or observation (control group) within 4 weeks after completion of standard adjuvant chemotherapy.